News

BioWorld Today: News To Note-Immune Design Corp.

June 28, 2013 - BioWorld Today

Immune Design Inc., of Seattle, and Medicago Inc., of Quebec City, entered a license agreement providing Medicago the use and commercialization of Immune Design’s synthetic Toll-like receptor 4 agonist, Glucopyranosyl Lipid A (GLA). Medicago has the option to use Immune Design’s molecular adjuvant in its vaccines for various pandemic influenza strains. Under the terms of the agreement, Immune Design granted Medicago a worldwide, nonexclusive license to research, develop and commercialize GLA as a component of its VLP-based vaccines in the field of pandemic influenza. Other terms were not disclosed.